The long -acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment see

DSpace Repository

The long -acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment see

Author: Rondeau, Eric; Scully, Marie; Ariceta, Gema; Barbour, Tom; Cataland, Spero; Heyne, Nils; Miyakawa, Yoshitaka; Ortiz, Stephan; Swenson, Eugene; Vallee, Marc; Yoon, Sung-Soo; Kavanagh, David; Haller, Hermann
Tübinger Autor(en):
Heyne, Nils
Published in: Kidney International (2020), Bd. 97, H. 6, S. 1287-1296
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/j.kint.2020.01.035
ISSN: 1523-1755
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)